Cerus (CERS) EBT Margin (2010 - 2026)

Cerus (CERS) posted EBT Margin of 5.03% for Q2 2026, down 73.22% sequentially from 2.9% in Q1 2026, and up 573.0% YoY from 0.75% in Q2 2025.

Cerus (CERS) EBT Margin (2010 - 2026) Analysis & Trends

Cerus has reported EBT Margin for 17 years, with the latest figure at 5.03% in Q2 2026.

Quarterly EBT Margin rose 573.0% year-over-year to 5.03% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 3.56% (up 541.0% YoY) and the FY2025 annual result came in at 7.57%, up 301.0% from the prior year.
EBT Margin fell to 5.03% in Q2 2026 per CERS's latest filing, from 2.9% in the prior quarter.
Over five years, EBT Margin peaked at 0.12% in Q3 2025 and troughed at 50.25% in Q1 2023.
A 5-year average of 16.09% and a median of 15.31% in 2025 frame the typical range for EBT Margin.
The sharpest annual moves came in 2022 and 2023: EBT Margin soared 4165 bps in 2022, then slumped 1765 bps in 2023.
Over 5 years, EBT Margin stood at 20.08% in 2022, then surged by 85 bps to 2.95% in 2023, then slumped by 42 bps to 4.19% in 2024, then slipped by 25 bps to 5.26% in 2025, then gained by 4 bps to 5.03% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 5.03%, 2.9%, and 5.26% for Q2 2026, Q1 2026, and Q4 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn	12.10%
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn	23.74%
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn	18.70%
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn	19.48%
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn	29.86%
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn	24.27%
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn	13.09%
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn	8.91%
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn	18.32%
10	Cerus	560.58 Mn	504.32 Mn	29.53 Mn	-5.03%

Download Data